Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery

Area of Science:

• Endocrinology and Metabolic Diseases
• Pharmaceutical Sciences
• Biomaterials Science

Background:

• Insulin monotherapy failure in diabetes mellitus is linked to glucoregulatory hormone dysregulation.
• Pramlintide, an adjunct to insulin, improves glycemic control by enhancing glucagon suppression.
• Current pramlintide therapy faces patient resistance due to separate injections and pharmacokinetic mismatches with insulin.

Purpose of the Study:

• To summarize challenges in codelivering insulin and pramlintide.
• To explore novel formulation strategies for pramlintide delivery.
• To improve patient adherence and diabetes management through optimized peptide codelivery.

Main Methods:

• Review of clinical studies on pramlintide efficacy in type 1 and type 2 diabetes.
• Analysis of pharmacokinetic differences between insulin and pramlintide.
• Investigation of formulation strategies including polymer-based systems, lipids, noncovalent conjugation, and amphiphilic excipients for codelivery.

Main Results:

• Pramlintide improves glycemic control, reduces postprandial glucose excursions, and promotes weight loss.
• Significant pharmacokinetic differences between insulin and pramlintide limit therapeutic efficacy.
• Various strategies are being explored to achieve synchronized release and codelivery of insulin and pramlintide.

Conclusions:

• Optimized codelivery systems for insulin and pramlintide can overcome current therapeutic limitations.
• Novel formulation strategies hold promise for improved diabetes management and patient quality of life.
• This work provides insights into peptide codelivery, potentially advancing diabetes treatment options.